StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) in a report released on Thursday. The brokerage set a "hold" rating on the specialty pharmaceutical company's stock.
Cumberland Pharmaceuticals Stock Performance
Shares of CPIX traded up $0.26 during mid-day trading on Thursday, hitting $5.34. The stock had a trading volume of 3,042,748 shares, compared to its average volume of 3,776,336. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The company has a market cap of $74.97 million, a PE ratio of -6.94 and a beta of 0.12. Cumberland Pharmaceuticals has a fifty-two week low of $1.04 and a fifty-two week high of $6.43. The company's fifty day simple moving average is $2.36 and its two-hundred day simple moving average is $1.66.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The business had revenue of $9.09 million during the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.
About Cumberland Pharmaceuticals
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
